110 - Anemia Management in CKD: New Paradigms for Iron Therapy and ESA Use

Contact hours available until 4/16/2016.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Speaker, Faculty, Planners and Authors Conflict of Interest Disclosure:
Beth St. John - Employee, Fresenius Medical Care
Planning disclosure: Anthony Pfaffle discloses that he receives other financial/material support as a Keryx contractor.
Speaker disclosure: Ajay Singh discloses that he receives grant/research support from Genetech, NIH, and Concert; that he is a consultant/speakers’ bureau for Keryx, Sandoz, Rockwell, Concert, Novartis, and GSK; and that he is on the advisory board for IHS Dialysis, Keryx, Medscape, and Rockwell.

Planning Committee:
• Annette Hood discloses that she is a member of the Amgen speakers’ bureau.
• Denise Murcek discloses other financial/material support as an employee of the VA Medical Center.
• Elizabeth St. John discloses other financial/material support as an employee of Fresenius Medical Care.
• Kyra Trappett discloses other financial/material support as an employee of DaVita.

Commercial Support and Sponsorship:
Supported by an educational grant from Keryx Biopharmaceuticals, Inc.

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

Objectives:   
• Review current KDOQI Anemia Guidelines and the impact of recent and potential changes.
• Discuss the pathophysiology of anemia of ESRD in the setting of anemia of chronic disease from other etiologies.
• Evaluate the effective and economical uses of iron and erythropoietin stimulating agents (ESAs) in combination and separately.
• Summarize the differing types of iron therapy.